OakChart

Praxis Precision Medicines Inc

PRAXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:07 PM ET

347.10+9.51 (2.82%)
2026-11-11 21:08 CET
Market cap
9,425.51 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-359.43 USD m
Free cash flow, TTM
-323.75 USD m
EPS diluted, TTM
-12.81
P/E
-
Compare

Price

PRAX against its 20, 50 and 200-day averages
2050200beat
200.00250.00300.00350.00400.001.0M2.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PRAXclose 347.1120-day 278.7650-day 291.12200-day 314.44347.1152w high

11.6% under the 52-week high of 392.70 on 20 Aug 2026. 52-week low 160.11 on 21 Nov 2025. Last 15 sessions, 40.2% high to low

Volume 1.20× normal · the line is the 50-bar volume average

Profile

PRAX
52-week range, 80% of the way up
160.11392.7

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

IndexRUT
Employees168
IPOOct 16, 2020
Beta2.82
ATR, 14d17.58
Rel volume1.20
Short float16.02%
Insider own5.95%
Inst own117.58%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap9.70B
Enterprise Value8.96B
Income-359.43M
Sales0.00M
Book/sh45.07
Cash/sh26.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees168
IPOOct 16, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B7.70
P/C13.02
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.53
Current Ratio14.53
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-12.81
EPS next Y-10.44
EPS next Q-4.11
EPS this Y-0.41%
EPS next Y22.85%
EPS next 5Y-
EPS past 3/5Y42.16% 13.34%
Sales past 3/5Y- -
EPS Y/Y TTM0.75%
Sales Y/Y TTM-100.00%
EPS Q/Q4.00%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.8.72% -

Ownership

Insider Own5.95%
Insider Trans-0.69%
Inst Own117.58%
Inst Trans8.70%
ROA-42.08%
ROE-44.84%
ROIC-28.54%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2024.52%
SMA5019.23%
SMA20010.39%
Trades-

Technical

Shs Outstand27.95M
Shs Float26.26M
Short Float16.02%
Short Ratio9.37
Short Interest4.21M
52W High392.70 -11.61%
52W Low160.11 116.79%
Volatility9.21% 5.82%
ATR (14)17.58
RSI (14)69.59
Beta2.82
Rel Volume1.20
Avg Volume448.84K
Volume470,773

Performance

Perf Week21.88%
Perf Month42.64%
Perf Quarter-5.80%
Perf Half Y0.08%
Perf YTD17.77%
Perf Year89.10%
Perf 3Y2261.26%
Perf 5Y13.60%
Perf 10Y-
Recom1.33
Target Price652.10
Prev Close337.59
Price347.10
Change %2.82%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedJJP MorganOverweight$700+101.7%
Oct 15, 2026InitiatedUUBSBuy$706+103.4%
Jul 13, 2026InitiatedGGoldmanBuy$447+28.8%
Jun 18, 2026InitiatedRRBC Capital MktsOutperform$449+29.4%
Apr 10, 2026InitiatedRRaymond JamesStrong Buy$815+134.8%
Feb 24, 2026InitiatedWWolfe ResearchOutperform$500+44.0%
Feb 02, 2026InitiatedWWells FargoEqual Weight$282-18.8%
Dec 15, 2025ReiteratedOOppenheimerOutperform$250 → $750+116.1%
Nov 19, 2025InitiatedBBTIG ResearchBuy$424+22.2%
Jun 02, 2025ResumedOOppenheimerOutperform$97-72.1%

Peers

Mkt cap
TickerCompanyMkt cap
XENEXenon Pharmaceuticals Inc4.14B
RAPPRapport Therapeutics Inc1.57B
JAZZJazz Pharmaceuticals plc15.87B
STOKStoke Therapeutics Inc1.80B
AXSMAxsome Therapeutics Inc7.80B
NBIXNeurocrine Biosciences Inc17.52B
BHVNBiohaven Ltd2.29B
ACADAcadia Pharmaceuticals Inc3.18B
SUPNSupernus Inc6.13B
BIIBBiogen Inc37.50B

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DeSimone JillDirectorJun 24 '26Option Exercise71.2011,600825,95413,937Jun 26 05:09 PM
DeSimone JillDirectorJun 24 '26Sale311.3211,6003,611,3352,337Jun 26 05:09 PM
DeSimone JillDirectorJun 24 '26Proposed Sale311.3211,6003,611,336Jun 24 04:18 PM
Nemiroff AlexGeneral Counsel and SecretaryNov 20 '25Option Exercise73.7625,1301,853,53145,962Nov 21 09:41 PM
Nemiroff AlexGeneral Counsel and SecretaryNov 20 '25Sale193.0925,1304,852,25620,832Nov 21 09:41 PM
Mastrocola LaurenPrincipal Accounting OfficerNov 20 '25Option Exercise61.1213,600831,25724,042Nov 21 09:39 PM
Mastrocola LaurenPrincipal Accounting OfficerNov 20 '25Sale192.0813,6002,612,24410,442Nov 21 09:39 PM
Nemiroff AlexOfficerNov 20 '25Proposed Sale193.0925,1304,852,249Nov 20 11:34 AM
Mastrocola LaurenOfficerNov 20 '25Proposed Sale192.0813,6002,612,239Nov 20 11:25 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 100
  • Guggenheim Names Top Biotechnology Stock (Investing.com)
  • Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire) +19.94%
  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.80%
  • Praxis Heads Into Q3 With Launch Costs Rising And Two FDA Decisions Just Ahead (Earnings Whispers)
  • Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation (GlobeNewswire) +6.69%
  • Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst calls (The Fly)
  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... (GuruFocus.com) +15.95%
  • These Two Stocks Hit Fresh 52-Week Highs Today DCTH Clocks Best Day In Nearly 15 Months (Stocktwits)
  • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire) +5.75%
  • Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-3.230-3.539-3.2300.000.0020
2026Q22026-08-06-2.870-3.668-2.8740.000.0019
2026Q12026-05-07-3.200-3.589-3.2050.000.0015
2025Q42026-02-19-3.500-3.126-3.5000.000.0716
2025Q32025-11-05-3.360-3.466-3.3640.000.0914
2025Q22025-08-04-3.310-3.247-3.3120.000.2112
2025Q12025-05-02-3.290-3.207-3.2910.000.2011
2024Q42025-02-28-2.940-2.847-2.9377.480.4011
2024Q32024-11-06-2.750-1.989-2.7490.300.3310
2024Q22024-08-13-1.740-2.315-1.7360.370.9310
2024Q12024-05-13-2.840-2.083-2.8450.421.887
2023Q42024-03-05-2.970-3.052-2.9660.510.006
2023Q32023-11-07-2.700-3.900-2.7250.500.006
2023Q22023-08-09-7.350-9.840-7.3800.790.005
2023Q12023-05-11-10.650-11.775-10.5800.460.004
2022Q42023-02-07-13.050-11.765-12.9760.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-117.99-44.400-27.5640.000.00
2021FY-59.100-55.525-59.0270.000.00
2022FY-69.600-67.911-69.6460.000.00
2023FY-18.690-20.428-18.6942.431.90
2024FY-10.210-10.184-10.2108.581.46
2025FY-13.480-13.106-13.4790.000.28
2026FY--13.535--0.68
2027FY--10.442--338.71
2028FY-5.058--1,095
2029FY-27.591--2,246
2030FY-50.880--3,606

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0914010.380.003.88
2026Q4S2026-10-2014010.630.003.88
2026Q4S2026-10-1714040.630.003.88
2026Q4S2026-10-1515040.590.003.88
2026Q4S2026-10-1415040.590.003.88
2026Q4S2026-09-2914040.630.003.88
2026Q4S2026-09-2214050.630.003.88
2026Q4S2026-09-0914060.630.003.88
2026Q4S2026-08-1516071.030.007.40
2026Q4S2026-08-0617070.970.007.40
2026Q4S2026-07-2117032.590.0012.14
2026Q4S2026-07-1617252.590.0012.14
2026Q4S2026-07-1017343.090.0012.14
2026Q4S2026-07-0916343.280.0012.14

Estimate history

EPS, annual-11.46-15.954-27.564-59.027-69.646-18.694-10.21-13.476-12.8075
Period20182019202020212022202320242025TTM
EPS, quarterly-2.749-2.937-3.291-3.312-3.364-3.5-3.205-2.874-3.23
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000002.4478.55300
Period20182019202020212022202320242025TTM
Sales, quarterly0.3027.4630000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.552.552.5513.023.2928.79219.42225.19527.948
Period20182019202020212022202320242025MRQ
Shares, quarterly17.78619.42220.34221.0421.16625.19527.8627.91727.948
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.008.552.450.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.130.140.360.431.171.590.750.680.00
Gross Profit-0.13-0.148.202.02-1.17-1.59-0.75-0.68-0.00
Selling, General and Administrative Excl. Other406.59326.06208.36128.39213.81165.7461.2235.1122.72
Research and Development289.11267.12152.4186.77155.04120.2644.9828.8818.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-406.72-326.20-200.16-126.37-214.99-167.33-61.97-35.79-22.72
Interest Expense0.000.000.000.000.000.000.000.000.13
Unusual Expense0.000.000.000.000.000.000.000.00-0.10
Net Income Before Taxes-359.43-303.27-182.82-123.28-214.03-167.06-61.83-35.60-26.40
Income Taxes0.000.000.000.000.000.00-0.01-0.080.13
Consolidated Net Income-359.43-303.27-182.82-123.28-214.03-167.06-61.33-35.51-26.93
Net Income From Continuing Operations-359.43-303.27-182.82-123.28-214.03-167.06-61.33-35.51-26.93
Net Income-359.43-303.27-182.82-123.28-214.03-167.06-70.32-40.68-29.22
EPS (Recurring)-12.32-13.48-10.21-18.69-69.65-59.03-27.56-15.95-11.49
EPS (Basic, Before Extraordinaries)-12.81-13.48-10.21-18.69-69.65-59.03-27.56-15.95-11.46
EPS (Diluted)-12.81-13.48-10.21-18.69-69.65-59.03-27.56-15.95-11.46
EBITDA-406.59-326.06-199.81-125.94-213.81-165.74-61.22-35.11-22.72
Non-Operating Income (Expense)47.3022.9317.353.100.960.270.140.19-3.66
Other After Tax Adjustments0.000.000.000.000.000.000.490.00-0.39
Stock Option Compensation Expense53.2533.9441.3624.8628.5922.693.800.490.42
Price To Sales Ratio--161.1360.04-----
Gross Margin--95.8182.35-----
Operating Margin---2,340.29-5,164.41-----
Net Margin---2,137.48-5,037.88-----
Shares Outstanding27.9525.2019.428.793.293.022.552.552.55
Market Capitalization9,425.519,425.511,434.37190.94111.54892.422,105.542,017.13-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.007.46
Cost of Goods Sold Incl. D&A0.030.030.040.030.020.050.050.05
Gross Profit-0.03-0.03-0.04-0.03-0.02-0.05-0.057.42
Selling, General and Administrative Excl. Other106.8896.87105.8297.0278.3476.0274.6871.37
Research and Development64.2069.4277.9977.5165.8063.0160.8156.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-106.91-96.90-105.86-97.04-78.36-76.07-74.73-63.96
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-94.23-83.72-92.56-88.91-73.93-71.13-69.30-58.68
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-94.23-83.72-92.56-88.91-73.93-71.13-69.30-58.68
Net Income From Continuing Operations-94.23-83.72-92.56-88.91-73.93-71.13-69.30-58.68
Net Income-94.23-83.72-92.56-88.91-73.93-71.13-69.30-58.68
EPS (Recurring)-3.23-2.87-3.20-3.50-3.36-3.31-3.29-2.94
EPS (Basic, Before Extraordinaries)-3.23-2.87-3.20-3.50-3.36-3.31-3.29-2.94
EPS (Diluted)-3.23-2.87-3.20-3.50-3.36-3.31-3.29-2.94
EBITDA-106.88-96.87-105.82-97.02-78.34-76.02-74.68-63.91
Non-Operating Income (Expense)12.6813.1813.308.134.424.945.435.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.8911.3117.119.947.457.778.798.57
Price To Sales Ratio----156.08116.2998.18179.78
Gross Margin-------99.37
Operating Margin--------856.97
Net Margin--------786.27
Shares Outstanding27.9527.9227.8625.2021.1721.0420.3419.42
Market Capitalization9,425.519,333.548,973.257,370.621,115.63856.52763.581,434.37

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments599.33392.5781.30100.49275.91297.2144.8117.95
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets11.5811.803.5810.3511.505.120.681.18
Total Current Assets610.91404.3784.88110.84287.41302.3345.5019.13
Net Property, Plant & Equipment0.241.362.653.874.870.841.580.10
Total Investments and Advances326.7677.380.420.420.000.000.600.60
Intangible Assets0.000.000.000.00---0.00
Deferred Tax Assets0.02-------
Other Assets0.000.000.000.000.470.010.020.00
Total Assets937.93483.1187.95115.13292.75303.1847.6919.83
Short Term Debt Incl. Current Port. of LT Debt0.111.261.131.000.810.760.700.00
Accounts Payable24.6312.535.8214.6710.784.092.673.39
Other Current Liabilities35.0323.768.8118.6726.8410.873.461.75
Total Current Liabilities59.7737.5515.7534.3438.4315.726.825.14
Long Term Debt0.000.111.372.503.500.000.760.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.02-------
Other Liabilities0.000.001.162.180.000.000.000.00
Total Liabilities59.7937.6618.2839.0241.9415.727.585.15
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00121.1255.72
Common Equity878.14445.4569.6776.11250.81287.46-81.01-41.04
Total Shareholders Equity878.14445.4569.6776.11250.81287.4640.1114.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity878.14445.4569.6776.11250.81287.4640.1114.68
Total Liabilities & Stockholders Equity937.93483.1187.95115.13292.75303.1847.6919.83
Book Value Per Share34.8522.937.9223.1283.05112.67-31.77-16.09
Tangible Book Value Per Share34.8522.937.9223.1283.05112.67-31.77-16.09
Full-Time Employees1681168210913967--
Price to Book Ratio7.493.582.201.063.567.32-16.36-
Return on Assets-42.68-64.03-121.41-104.95-56.07-34.96-105.18-
Return on Equity-45.83-70.98-169.13-130.94-62.07-37.44-129.62-
Return on Invested Capital-34.54-41.03-173.54-272.30-65.69-21.33-86.88-183.40
Quick Ratio10.2210.775.393.237.4819.236.673.72
Current Ratio10.2210.775.393.237.4819.236.673.72

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-359.43-303.27-182.82-123.28-214.03-167.06-61.82-35.51-26.54
Depreciation0.130.140.360.430.420.180.050.040.00
Other Funds (Non Cash)51.5131.3839.7825.7430.3526.195.911.314.35
Funds from Operations-307.78-271.75-142.68-97.10-183.26-140.69-55.86-34.16-22.18
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-14.1122.6810.92-13.03-0.9716.903.941.381.46
Cash from Operating Activities-321.89-249.07-131.76-110.13-184.23-123.79-51.93-32.79-20.72
Capital Expenditures-5.86-0.060.00-0.05-0.44-1.050.00-0.10-0.06
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-687.93-311.09-248.4939.0097.33-139.470.000.000.00
Purchase of Investments-1,111.04-623.81-371.520.00-83.02-164.170.000.000.00
Sale Or Maturity of Investments423.12312.72123.0339.00180.3524.700.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-693.78-311.15-248.4938.9596.89-140.520.00-0.10-0.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1,241.99704.26514.6392.0110.72107.59304.4260.3936.80
Repurchase of Common Pref Stock0.000.000.000.000.000.00-30.000.000.00
Sale of Common Pref Stock1,241.99704.26514.6392.0110.72107.59334.4260.3936.80
Proceedsfrom Stock Options1,222.96690.99512.0091.599.30105.14334.4260.3936.80
Issuance or Reduction of Debt, Net0.130.000.00-1.00-0.81-0.76-0.70-0.631.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-14.54-2.09-0.31-0.14-0.260.000.000.000.00
Other Financing Activities Uses-14.54-2.09-0.31-0.14-0.260.000.000.000.00
Cash from Financing Activities1,227.58702.17514.3290.879.65106.82303.7259.7637.80
Net Change in Cash211.91141.96134.0719.68-77.69-157.49251.7926.8617.02
Free Cash Flow-323.75-249.12-131.76-110.18-184.68-124.84-51.93-32.89-20.78
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments745.32758.55786.87599.33267.16301.27
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets17.4813.3510.9111.586.695.30
Total Current Assets762.80771.90797.77610.91273.84306.58
Net Property, Plant & Equipment2.581.491.490.240.540.88
Total Investments and Advances540.70615.29660.94326.76122.01145.37
Intangible Assets-0.770.000.000.000.00
Deferred Tax Assets---0.02--
Other Assets6.000.640.000.000.000.00
Total Assets1,312.071,390.101,460.20937.93396.39452.83
Short Term Debt Incl. Current Port. of LT Debt0.731.091.440.110.440.76
Accounts Payable15.0223.3931.1624.6330.8228.83
Other Current Liabilities36.7524.5917.6535.0321.6319.02
Total Current Liabilities52.5049.0650.2459.7752.8848.61
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.02--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities52.5049.0650.2459.7952.8848.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,259.581,341.041,409.96878.14343.50404.22
Total Shareholders Equity1,259.581,341.041,409.96878.14343.50404.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,259.581,341.041,409.96878.14343.50404.22
Total Liabilities & Stockholders Equity1,312.071,390.101,460.20937.93396.39452.83
Book Value Per Share45.0748.0450.6134.8516.2319.21
Tangible Book Value Per Share45.0748.0150.6134.8516.2319.21
Full-Time Employees---168--
Price to Book Ratio7.496.629.2418.162.761.95
Return on Assets-42.08-36.80-33.68-42.68-67.20-56.16
Return on Equity-44.84-38.86-35.32-45.83-75.20-60.98
Return on Invested Capital-7.48-6.24-6.56-10.12-21.52-17.60
Quick Ratio14.5315.7315.8810.225.186.31
Current Ratio14.5315.7315.8810.225.186.31

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-94.23-83.72-92.56-88.91-73.93-71.13
Depreciation0.030.030.040.030.020.05
Other Funds (Non Cash)14.3910.9416.659.537.007.04
Funds from Operations-79.81-72.75-75.87-79.35-66.91-64.04
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.57-4.45-10.182.092.179.68
Cash from Operating Activities-81.38-77.19-86.05-77.26-64.74-54.37
Capital Expenditures-4.78-1.02-0.060.000.00-0.06
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-27.3212.00-344.21-328.3950.4117.95
Purchase of Investments-156.72-77.27-486.78-390.27-75.13-41.35
Sale Or Maturity of Investments129.4089.27142.5761.88125.5559.30
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-32.1010.98-344.27-328.3950.4117.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.424.88622.35613.346.8128.65
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.424.88622.35613.346.8128.65
Proceedsfrom Stock Options0.000.00621.24601.736.0028.36
Issuance or Reduction of Debt, Net-0.35-0.35-0.100.93-0.32-0.31
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.49-0.31-12.92-0.82-0.05-0.02
Other Financing Activities Uses-0.49-0.31-12.92-0.82-0.05-0.02
Cash from Financing Activities0.574.22609.33613.456.4428.32
Net Change in Cash-112.91-61.99179.00207.80-7.89-8.15
Free Cash Flow-82.94-77.44-86.11-77.26-64.74-54.42

Revenue breakdown

Pharmaceutical Preparations2024: 8.55M
United States2024: 8.55M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.02%4.2M26.3M459.05K
2026-10-1514.94%3.9M26.3M429.77K
2026-09-3015.95%4.2M26.3M408.25K
2026-09-1514.45%3.8M26.3M435.16K
2026-08-3114.25%3.7M26.3M501.05K
2026-08-1414.15%3.7M26.3M492.76K
2026-07-3113.98%3.7M26.2M481.75K
2026-07-1514.41%3.8M26.1M498.43K
2026-06-3015.28%4.0M26.1M494.17K
2026-06-1513.68%3.6M26.1M444.17K
2026-05-2913.99%3.7M26.1M397.12K
2026-05-1514.21%3.7M26.1M414.77K
2026-04-3014.41%3.8M26.2M423.70K
2026-04-1514.79%3.8M25.6M451.75K
2026-03-3115.47%4.0M25.6M492.55K
2026-03-1314.64%3.7M25.6M526.11K
2026-02-2714.81%3.8M25.6M642.56K
2026-02-1314.88%3.8M25.5M754.71K
2026-01-3015.27%3.9M25.3M796.21K
2026-01-1514.83%3.7M25.3M1.11M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call125216.92260.004.3920.000.000.982-0.4850.023
call130211.72210.004.1900.000.000.982-0.4840.024
call135206.92161944.1380.000.000.981-0.4830.025
call140201.62110.003.9500.000.000.980-0.4820.026
call145196.62062343.8570.000.000.980-0.4800.027
call150192.12012293.7650.000.000.979-0.4790.027
call155187.2196224.13.6560.000.000.978-0.4770.028
call160181.319196.893.4321.000.000.977-0.4750.029
call1651771860.003.3520.000.000.976-0.4740.030
call170171.81810.003.2900.000.000.976-0.4720.031
call175166.9176205.13.0860.000.000.975-0.4700.032
call180162.41710.002.9950.000.000.974-0.4670.033
call1851571661952.8360.000.000.973-0.4650.034
call190152.21610.002.7340.000.000.972-0.4630.035
call195147.11560.002.6680.000.000.971-0.4600.036
call2001421510.002.5370.000.000.969-0.4570.037
call210132.11410.002.3810.000.000.967-0.4510.040
call220122.2131.90.002.1710.000.000.964-0.4450.043
call230112.21220.002.0910.000.000.961-0.4380.046
call240102.111244.001.9202.000.000.958-0.4300.049
call25092.8010239.931.77638.000.000.950-0.4600.056
call26083.1092.0034.001.62411.000.000.897-0.9240.097
call27074.1082.0043.751.44514.000.000.887-0.8930.104
call28065.0073.0060.001.38027.001.000.866-0.9390.117
call29056.3064.0064.901.29938.007.000.845-0.9470.129
call30048.4056.0046.551.2733141.000.803-1.0860.150
call31040.5048.0035.001.22057.000.000.777-1.0100.162
call32033.3040.8031.001.1903730.000.706-1.2580.187
call33026.7034.0026.851.15317.002.000.648-1.3050.201
call34021.0028.6024.401.1552094.000.584-1.3560.211
call35017.2021.5019.001.0482993.000.515-1.2900.216
call36013.3016.9014.001.0282371.000.447-1.2850.214
call3709.0014.8012.001.0605.003.000.400-1.3000.210
call3807.8011.909.501.09984.0033.000.332-1.2310.197
call3905.409.007.501.0761.001.000.273-1.1010.180
call4004.006.005.861.01719.000.000.208-0.8950.155
call4100.107.302.681.11619.000.000.194-0.9430.149
call4200.055.602.651.19021.000.000.175-0.9410.140
call4300.056.403.931.27713.000.000.166-0.9780.135
call4400.056.400.001.3650.000.000.158-1.0110.131
call4500.056.302.151.4496.000.000.151-1.0420.127
call4600.106.100.001.5300.000.000.146-1.0710.124
call4700.058.100.001.6070.000.000.140-1.0970.121
call4800.056.400.001.6820.000.000.136-1.1220.118
call4900.054.900.001.6910.000.000.121-1.0420.109
call5000.004.904.901.75031.001.000.118-1.0570.107
call5200.004.905.261.8930.000.000.111-1.0960.103
call5300.004.900.001.9830.000.000.119-1.2100.109
call5400.004.900.002.0440.000.000.116-1.2270.107
call5500.004.900.002.1040.000.000.114-1.2440.106
call5600.004.900.002.1320.000.000.102-1.1580.096
call5700.004.900.452.1880.001.000.100-1.1720.095
call5800.054.900.202.2426.000.000.098-1.1850.094
put1250.004.900.003.5810.000.00-0.018-0.4710.023
put1300.004.900.003.4490.000.00-0.018-0.4690.024
put1350.004.900.003.3310.000.00-0.019-0.4670.025
put1400.004.900.003.2400.000.00-0.019-0.4670.026
put1450.004.900.003.0910.000.00-0.021-0.4630.027
put1500.004.900.053.0021.000.00-0.021-0.4590.027
put1550.004.900.002.8970.000.00-0.022-0.4570.028
put1600.004.900.002.7950.000.00-0.022-0.4550.029
put1650.004.900.002.6970.000.00-0.023-0.4520.030
put1700.004.906.002.6021.000.00-0.024-0.4500.031
put1750.004.906.702.5091.000.00-0.025-0.4470.032
put1800.004.900.052.4191.000.00-0.026-0.4450.033
put1850.002.000.051.9290.000.00-0.019-0.2570.026
put1900.004.901.902.25046.000.00-0.028-0.4410.035
put1950.004.900.002.1620.000.00-0.029-0.4360.036
put2000.004.900.202.06716.000.00-0.031-0.4350.037
put2100.004.900.501.9021590.00-0.033-0.4270.040
put2200.052.501.001.7462020.00-0.036-0.4180.043
put2300.004.902.001.6282.000.00-0.038-0.4110.045
put2400.001.501.371.49817.000.00-0.041-0.4030.048
put2500.151.701.501.37259.000.00-0.050-0.4310.056
put2600.004.9022.101.78712.000.00-0.115-1.0530.106
put2700.104.906.201.47415.000.00-0.114-0.8600.104
put2800.105.6034.901.37014.000.00-0.134-0.8930.117
put2900.556.1050.301.26725.000.00-0.155-0.9150.129
put3003.808.303.731.27727.002.00-0.193-1.0660.149
put3104.808.204.801.1088.001.00-0.218-0.9910.160
put3207.1013.007.101.20416.002.00-0.286-1.2360.185
put33010.0016.0022.001.1291.000.00-0.352-1.2680.201
put34013.9020.0024.701.10521.000.00-0.416-1.3190.211
put35018.4024.4025.701.0463.000.00-0.485-1.2520.216
put36024.2031.000.001.1050.000.00-0.553-1.2450.214
put37031.0038.000.001.1320.000.00-0.610-1.2620.208
put38039.0045.6086.491.1641.000.00-0.668-1.1890.197
put39047.0053.700.001.2000.000.00-0.727-1.0570.180
put40055.4063.400.001.3060.000.00-0.791-0.8490.155
put41063.0072.200.001.3400.000.00-0.806-0.8970.149
put42072.0081.000.001.3850.000.00-0.824-0.8940.140
put43081.0090.200.001.4190.000.00-0.834-0.9300.135
put44091.00100.40.001.5120.000.00-0.842-0.9620.131
put450100109.70.001.5280.000.00-0.849-0.9920.127
put460110119.20.001.6120.000.00-0.854-1.0200.124
put470120128.90.001.6120.000.00-0.860-1.0450.121
put480129.6138.20.001.6880.000.00-0.864-1.0690.118
put4901401480.001.7610.000.00-0.879-0.9870.109
put5001501580.001.8320.000.00-0.883-1.0050.107
put520170177.80.001.9480.000.00-0.889-1.0390.103
put530179188.60.002.0310.000.00-0.891-1.0550.101
put540189198.40.002.0940.000.00-0.894-1.0690.099
put550199208.60.002.1550.000.00-0.896-1.0830.098
put560209217.60.002.1750.000.00-0.898-1.0960.096
put570219227.60.002.2320.000.00-0.900-1.1090.095
put580229237.62202.2880.000.00-0.902-1.1210.094

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-05SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-07-028-KCurrent report2026-06-29SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-24144Filing for proposed sale of securities under Rule 144.SEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-128-KCurrent report2026-06-10SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06003.61M1
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-11007.46M2

Institutional holders

Manager% owned
Jupiter Topco LLC12.27%
FMR LLC9.45%
BlackRock, Inc.8.22%
PERCEPTIVE ADVISORS LLC7.30%
BAKER BROS. ADVISORS LP6.29%
Orbis Allan Gray Ltd5.49%
VANGUARD PORTFOLIO MANAGEMENT LLC4.79%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
STATE STREET CORP3.68%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.64%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.34%
VANGUARD SMALL-CAP INDEX FUND2.29%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.48%
Select Biotechnology Portfolio1.47%
VANGUARD SMALL-CAP VALUE INDEX FUND1.45%
Janus Henderson Global Life Sciences Fund1.36%
Janus Henderson Enterprise Fund1.28%
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Small Cap Index Fund0.99%

OakChart. PRAX. Cached 15 minutes.